Abstract
Background: Primary care services frequently provide the initial contact between people with dementia and health service providers. Early diagnosis and screening programmes have been suggested as a possible strategy to improve the identification of such individuals and treatment and planning health and social care support.
Objective: To determine what early diagnostic and screening programmes have been adopted in primary care practice, to explore who should deliver these and to determine the possible positive and negative effects of an early diagnostic and screening programme for people with dementia in primary care.
Methods: A systematic review of the literature was undertaken using published and unpublished research databases. All papers answering our research objectives were included. A narrative analysis of the literature was undertaken, with the CASP tools used appropriately to assess study quality.
Results: Thirty-three papers were identified of moderate to high quality. The limited therapeutic options for those diagnosed with dementia means that even if such a programme was instigated, the clinical value remains questionable. Furthermore, accuracy of the diagnosis remains difficult to assess due to poor evidence and this raises questions regarding whether people could be over- or under-diagnosed. Given the negative social and psychological consequences of such a diagnosis, this could be devastating for individuals.
Conclusion: Early diagnostic and screening programmes have not been widely adopted into primary care. Until there is rigorous evidence assessing the clinical and cost-effectiveness of such programmes, there remains insufficient evidence to support the adoption of these programmes in practice.
Keywords: Diagnostic, population screening, cognitive impairment, experiences, general practice, community services.
Current Alzheimer Research
Title:Systematic Review Investigating Multi-disciplinary Team Approaches to Screening and Early Diagnosis of Dementia in Primary Care – What are the Positive and Negative Effects and Who Should Deliver It?
Volume: 15 Issue: 1
Author(s): Toby Smith , Jane Cross, Fiona Poland , Felix Clay, Abbey Brookes, Ian Maidment, Bridget Penhale, Ken Laidlaw and Chris Fox*
Affiliation:
- Norwich Medical School, University of East Anglia, Norwich,United Kingdom
Keywords: Diagnostic, population screening, cognitive impairment, experiences, general practice, community services.
Abstract: Background: Primary care services frequently provide the initial contact between people with dementia and health service providers. Early diagnosis and screening programmes have been suggested as a possible strategy to improve the identification of such individuals and treatment and planning health and social care support.
Objective: To determine what early diagnostic and screening programmes have been adopted in primary care practice, to explore who should deliver these and to determine the possible positive and negative effects of an early diagnostic and screening programme for people with dementia in primary care.
Methods: A systematic review of the literature was undertaken using published and unpublished research databases. All papers answering our research objectives were included. A narrative analysis of the literature was undertaken, with the CASP tools used appropriately to assess study quality.
Results: Thirty-three papers were identified of moderate to high quality. The limited therapeutic options for those diagnosed with dementia means that even if such a programme was instigated, the clinical value remains questionable. Furthermore, accuracy of the diagnosis remains difficult to assess due to poor evidence and this raises questions regarding whether people could be over- or under-diagnosed. Given the negative social and psychological consequences of such a diagnosis, this could be devastating for individuals.
Conclusion: Early diagnostic and screening programmes have not been widely adopted into primary care. Until there is rigorous evidence assessing the clinical and cost-effectiveness of such programmes, there remains insufficient evidence to support the adoption of these programmes in practice.
Export Options
About this article
Cite this article as:
Smith Toby, Cross Jane, Poland Fiona, Clay Felix , Brookes Abbey, Maidment Ian, Penhale Bridget, Laidlaw Ken and Fox Chris*, Systematic Review Investigating Multi-disciplinary Team Approaches to Screening and Early Diagnosis of Dementia in Primary Care – What are the Positive and Negative Effects and Who Should Deliver It?, Current Alzheimer Research 2018; 15 (1) . https://dx.doi.org/10.2174/1567205014666170908094931
DOI https://dx.doi.org/10.2174/1567205014666170908094931 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of microRNAs in the Development of Type 2 Diabetes Complications
Current Pharmaceutical Design From Stem Cells to Dopamine Neurons: Developmental Biology Meets Neurodegeneration
CNS & Neurological Disorders - Drug Targets Intracellular Aβ and its Pathological Role in Alzheimer’s Disease: Lessons from Cellular to Animal Models
Current Alzheimer Research Postprandial Glucose - A Potential Therapeutic Target to Reduce Cardiovascular Mortality
Current Vascular Pharmacology Genetic Variants in Diseases of the Extrapyramidal System
Current Genomics Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Neurological Disorders in Pregnancy
Current Women`s Health Reviews Recent Patent Advances for Neurodegenerative Disorders and its Treatment
Recent Patents on Drug Delivery & Formulation The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design Current State of Saliva Biomarkers for Aging and Alzheimer’s Disease
Current Alzheimer Research Valproic Acid Attenuates Neuronal Loss in the Brain of APP/PS1 Double Transgenic Alzheimer’s Disease Mice Model
Current Alzheimer Research Ion Channels on Microglia: Therapeutic Targets for Neuroprotection
CNS & Neurological Disorders - Drug Targets Introduction: Advancing Drug Discovery for Alzheimers Disease [ ISOA Fifth Annual Investigators Meeting “Recent Advances in Drug Discovery and Development for Alzheimers Disease” Sponsored by Elan Pharmaceuticals Inc, The Graphic Expression, Glaxo Smith Kline Pharmaceuticals, Neurochem Inc, Pfizer Inc. (Guest Editors: Howard M. Fillit and Lorenzo M. Refolo)]
Current Alzheimer Research Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Neurodegeneration in Amygdala Precedes Hippocampus in the APPswe/ PS1dE9 Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Cerebrovascular Damage as a Cause for Alzheimers Disease
Current Neurovascular Research Tolfenamic Acid Prevents Amyloid β-induced Olfactory Bulb Dysfunction In Vivo
Current Alzheimer Research Gene-environment Interactions in Late Life: Linking Psychosocial Stress with Brain Aging
Current Neuropharmacology Antioxidants in Health, Disease and Aging
CNS & Neurological Disorders - Drug Targets Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design